Abstract
Executive Summary
Unmet needs across the hematological malignancies remain high, with most
traditional therapies conferring low levels of specificity and high toxicity.
There are today more than 390 therapeutics targeting hematological cancers,
from early preclinical to marketed drugs. Hematological Cancers Drug Pipeline
Update lists all drugs and gives you a progress analysis on each one of them.
Identified drugs are linked to 197 different targets. These targets are
further categorized on the CD-ROM by 50 classifications of molecular function
and with pathway referals to BioCarta, KEGG and NetPath. Read more below on
how the Hematological Cancers Drug Pipeline Update is organized.
How May Drug Pipeline Update Be of Use?
- Show investors/board/management that you are right on top of drug
development progress in your therapeutic area.
- Find competitors, collaborations partners, M&A candidates etc.
- Jump start competitive drug intelligence operations
- Excellent starting point for world wide benchmarking
- Compare portfolio and therapy focus with your peers
- Speed up pro-active in-/out licensing strategy work
- Fast and easy way of tracking drugs using search engines; just one click
from inside the application and you may search the World Wide Web and PubMed
for any drug.
View Cart
